Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12960278

Antimicrobial polypeptides.

Tomas Ganz
View original source ↗Export metadata ↓

Abstract

The respiratory tract presents a large and potentially vulnerable surface to inhaled microbes. It is coated by a thin layer of secretions generated by airway epithelial cells, submucosal glands, resident and recruited phagocytes (neutrophils, eosinophils, monocytes, and macrophages) and alveolar epithelial cells, as well as substances that enter from blood plasma. More than 80 years ago, Alexander Fleming observed that respiratory secretions have microbicidal and microbistatic properties. He described the activity of lysozyme, one of the principal polypeptides of these secretions. Since then, a number of additional antimicrobial components have been identified, and there is increasing insight into their complex interactions. This review is an update of my previous summary of this area.

Explore related subjects

Antimicrobial Cationic PeptidesHumansMuramidasePulmonary Disease, Chronic ObstructiveRespiratory MucosaRespiratory Tract DiseasesJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Review

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tomas Ganz. 2003-07-15. Antimicrobial polypeptides.. https://doi.org/10.1189/jlb.0403150

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

DmAMP1, an antifungal plant defensin from dahlia (Dahlia merckii), interacts with sphingolipids from Saccharomyces cerevisiae.

DmAMP1, an antifungal plant defensin from Dahlia merckii, was shown previously to require the presence of sphingolipids for fungicidal action against Saccharomyces cerevisiae. Sphingolipids may stabilize glycosylphosphatidylinositol (GPI)-anchored proteins, which interact with DmAMP1, or they may directly serve as DmAMP1 binding sites. In the present study, we demonstrate that S. cerevisiae disruptants in GPI-anchored proteins showed small or no increased resistance towards DmAMP1 indicating no involvement of these proteins in DmAMP1 action. Further, studies using an enzyme-linked immunosorbent assay (ELISA)-based binding assay revealed that DmAMP1 interacts directly with sphingolipids isolated from S. cerevisiae and that this interaction is enhanced in the presence of equimolar concentrations of ergosterol. Therefore, DmAMP1 antifungal action involving membrane interaction with sphingolipids and ergosterol is proposed.

Antimicrobial Cationic Peptides↗
PubMed2003

IPT1-independent sphingolipid biosynthesis and yeast inhibition by syringomycin E and plant defensin DmAMP1.

Both bacterial cyclic lipodepsipeptide syringomycin E and plant defensin DmAMP1 were shown previously to require expression of the yeast gene IPT1 for fungicidal action against Saccharomyces cerevisiae. IPT1 encodes a sphingolipid biosynthetic pathway glycotransferase that produces the terminal sphingolipid mannosyldiinositolphosphoceramide. However, when grown in half-strength potato dextrose medium, an ipt1 deletion mutant of S. cerevisiae was observed to be sensitive to syringomycin E and DmAMP1 and to produce small amounts of mannosyldiinositolphosphoceramide. These results show that the terminal sphingolipid but not IPT1 expression is required for fungicidal activity, and they suggest an IPT1-independent route for mannosyldiinositolphosphoceramide biosynthesis.

Antimicrobial Cationic Peptides↗
PubMed2003

The pharmacophore of short cationic antibacterial peptides.

Cationic antibacterial peptides have been proclaimed as new drugs against multiresistant bacteria. Their limited success so far is partially due to the size of the peptides, which gives rise to unresolved issues regarding administration, bioavailability, metabolic stability, and immunogenicity. We have systematically investigated the minimum antibacterial motif of cationic antibacterial peptides regarding charge and lipophilicity/bulk and found that the pharmacophore was surprisingly small, opening the opportunity for development of short antibacterial peptides for systemic use.

Antimicrobial Cationic Peptides↗